{
  "retracted": false,
  "timestamp": 1541030400000,
  "updates": [
    {
      "timestamp": 1574386809590,
      "identifier": {
        "doi": "10.1016/j.ejca.2018.09.022"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.ejca.2018.02.012"
  },
  "journal": "European Journal of Cancer",
  "publisher": "Elsevier BV",
  "title": "Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]"
}
